Comparison · NCT01529112-sae
Lenvatinib vs Lenvatinib Matched Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lenvatinib vs Lenvatinib Matched Placebo: serious adverse events. Trial comparisons, record NCT01529112-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01529112-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.517 | 0.415 | 0.618 | wilson | |
| Risk in group 2 | 0.457 | 0.322 | 0.598 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0603 | -0.114 | 0.229 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.13 | 0.779 | 1.65 | log | |
| Odds ratio, group 1 over group 2 | 1.27 | 0.624 | 2.6 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Lenvatinib than on Lenvatinib Matched Placebo | 16.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lenvatinib | Participants received lenvatinib 24 mg orally, once daily continuously in each 28-day treatment cycle. | 46 | 89 | EG000 |
| Group 2 | Lenvatinib Matched Placebo | Participants received lenvatinib matched placebo orally, once daily continuously in each 28-day treatment cycle. | 21 | 46 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- For each participant, from the first dose till 30 days after the last dose or up to approximately 2 years (data cut-off date of 21 January 2014)
Source ClinicalTrials.gov
Trial
- Title
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
- NCT number
- NCT01529112
- Phases
- PHASE2
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Lenvatinib, Lenvatinib matched placebo, BSC
- Lead sponsor
- Eisai Inc.
- Results first posted
- 2016-02-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01529112?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01529112-sae